Suppression of HUVEC tissue factor synthesis by antisense oligodeoxynucleotide

Area of Science:

• Biochemistry
• Molecular Biology
• Cell Biology

Background:

• Tissue factor (TF) is crucial for initiating blood coagulation and has non-hemostatic roles in inflammation and angiogenesis.
• Dysregulated TF expression, particularly in sepsis, can lead to disseminated intravascular coagulation.
• Targeting TF offers a potential therapeutic strategy for various diseases.

Purpose of the Study:

• To investigate the feasibility of inhibiting lipopolysaccharide (LPS)-induced TF expression in human umbilical vein endothelial cells (HUVECs).
• To evaluate the efficacy of a modified phosphorothioate antisense oligodeoxynucleotide delivered via CD31 receptor-mediated endocytosis.

Main Methods:

• Cultured HUVECs were treated with a TF antisense oligomer conjugated to an anti-CD31 antibody.
• Cells were co-exposed to lipopolysaccharide (LPS) and the TF antisense conjugate.
• TF activity, TF mRNA levels, and cytotoxicity were assessed.

Main Results:

• TF antisense oligomer conjugate significantly suppressed LPS-induced TF activity by 54.6+/-3.2%.
• The treatment also reduced LPS-induced TF mRNA levels.
• Control experiments confirmed the specificity of the antisense effect, and no significant cytotoxicity was observed.

Conclusions:

• Modified TF antisense oligomers, delivered via CD31 receptor-mediated endocytosis, specifically inhibit endothelial TF synthesis.
• Antisense oligomers represent a valuable tool for studying endothelial TF function and biology.
• This approach holds potential for therapeutic interventions targeting TF-mediated processes.